Harvard Bioscience (HBIO) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 37.5% versus a loss of 26.6%. Over five years, HBIO leads with a -87.4% price change compared with -93.0% for PACB. Pacific Biosciences of California is the larger company by market cap ($508.9 million vs $39.6 million), about 12.9 times the size.
Harvard Bioscience converts more of its revenue into profit, with a net margin of -65.5% versus -341.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | PACB |
|---|---|---|
| Share price | $8.66 | $1.63 |
| Market cap | $39.60M | $508.95M |
| 1-day change | -0.23% | -7.39% |
| YTD return | +29.25% | -12.83% |
| 1-year return | +37.46% | -26.58% |
| 5-year return | -87.45% | -93.01% |
| Forward P/E | 16.34 | — |
| EPS (TTM) | $-2.59 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $86.55M | $160.00M |
| Revenue growth (YoY) | -8.06% | +3.89% |
| Net income (latest FY) | $-56.70M | $-546.38M |
| Gross margin | 57.67% | 28.61% |
| Operating margin | -56.13% | -346.15% |
| Net margin | -65.51% | -341.47% |
| 52-week high | $10.20 | $3.44 |
| 52-week low | $4.00 | $1.07 |
| Distance from 52-week high | -15.10% | -52.62% |
| Analyst consensus | none | buy |
| Avg. price target upside | -13.39% | +68.10% |
| Average volume | 21.82K | 13.23M |
| Shares outstanding | 4.57M | 312.24M |
| Employees | 316 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacific Biosciences of California is about 12.9 times larger than Harvard Bioscience by market value ($508.95M vs $39.60M).
- HBIO has outperformed PACB by 64.0 percentage points over the past year.
- Harvard Bioscience is more profitable, keeping -65.5 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
- Pacific Biosciences of California grew revenue faster in its latest fiscal year (+3.89% vs -8.06%).
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
HBIO vs PACB FAQ
Which is bigger, Harvard Bioscience or Pacific Biosciences of California?
Pacific Biosciences of California (PACB) is larger, with a market capitalization of $508.95M compared with $39.60M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or PACB?
HBIO returned +37.46% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.